These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 17572261

  • 1. The evidence for the use of recombinant human activated factor VII in the treatment of bleeding patients with quantitative and qualitative platelet disorders.
    Poon MC.
    Transfus Med Rev; 2007 Jul; 21(3):223-36. PubMed ID: 17572261
    [Abstract] [Full Text] [Related]

  • 2. New Insights Into the Treatment of Glanzmann Thrombasthenia.
    Poon MC, Di Minno G, d'Oiron R, Zotz R.
    Transfus Med Rev; 2016 Apr; 30(2):92-9. PubMed ID: 26968829
    [Abstract] [Full Text] [Related]

  • 3. Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.
    Poon MC.
    Vasc Health Risk Manag; 2007 Apr; 3(5):655-64. PubMed ID: 18078017
    [Abstract] [Full Text] [Related]

  • 4. Treatment of bleeding in patients with platelet disorders: is there a place for recombinant factor VIIa?
    Laurian Y.
    Pathophysiol Haemost Thromb; 2002 Apr; 32 Suppl 1():37-40. PubMed ID: 12214146
    [Abstract] [Full Text] [Related]

  • 5. Low Concentrations of Recombinant Factor VIIa May Improve the Impaired Thrombin Generation of Glanzmann Thrombasthenia Patients.
    Levy-Mendelovich S, Levy T, Budnik I, Barg AA, Rosenberg N, Seligsohn U, Kenet G, Livnat T.
    Thromb Haemost; 2019 Jan; 119(1):117-127. PubMed ID: 30597506
    [Abstract] [Full Text] [Related]

  • 6. Management of thrombocytopenic bleeding: is there a role for recombinant coagulation factor VIIa?
    Poon MC.
    Curr Hematol Rep; 2003 Mar; 2(2):139-47. PubMed ID: 12901145
    [Abstract] [Full Text] [Related]

  • 7. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U, Erhardtsen E.
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [Abstract] [Full Text] [Related]

  • 8. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents.
    Poon MC, Zotz R, Di Minno G, Abrams ZS, Knudsen JB, Laurian Y.
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S33-6. PubMed ID: 16427383
    [Abstract] [Full Text] [Related]

  • 9. A novel approach to improving recombinant factor VIIa activity with a preserved platelet preparation.
    Campbell RA, Fischer TH, Wolberg AS.
    Br J Haematol; 2007 Jul; 138(1):82-93. PubMed ID: 17555451
    [Abstract] [Full Text] [Related]

  • 10. Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature.
    Rajpurkar M, Chitlur M, Recht M, Cooper DL.
    Haemophilia; 2014 Jul; 20(4):464-71. PubMed ID: 24948404
    [Abstract] [Full Text] [Related]

  • 11. Treatment of inherited platelet disorders.
    Seligsohn U.
    Haemophilia; 2012 Jul; 18 Suppl 4():161-5. PubMed ID: 22726101
    [Abstract] [Full Text] [Related]

  • 12. Intensive menstrual bleeding successfully treated with recombinant factor VIIa in Glanzmann thrombasthenia.
    Balci YI, Karabulut A, Kabukcu S, Sari I, Keskin A.
    Clin Appl Thromb Hemost; 2011 Aug; 17(4):320-2. PubMed ID: 20460355
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of rFVIIa in 4 children with Glanzmann thrombasthenia.
    Valentino LA.
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):653-8. PubMed ID: 17023825
    [Abstract] [Full Text] [Related]

  • 15. Independent adjudicator assessments of platelet refractoriness and rFVIIa efficacy in bleeding episodes and surgeries from the multinational Glanzmann's thrombasthenia registry.
    Recht M, Rajpurkar M, Chitlur M, d'Oiron R, Zotz R, Di Minno G, Cooper DL, Poon MC.
    Am J Hematol; 2017 Jul; 92(7):646-652. PubMed ID: 28370369
    [Abstract] [Full Text] [Related]

  • 16. Experiences with recombinant human factor VIIa in patients with thrombocytopenia.
    Goodnough LT.
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):25-9. PubMed ID: 14872417
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
    Murkin JM.
    Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
    [Abstract] [Full Text] [Related]

  • 19. Understanding the therapeutic action of recombinant factor VIIa in platelet disorders.
    Hers I, Mumford A.
    Platelets; 2008 Dec; 19(8):571-81. PubMed ID: 19012175
    [Abstract] [Full Text] [Related]

  • 20. Recombinant activated factor VII for hemostatic cover of orthopedic interventions in a girl with thrombocytopenia with absent radii syndrome.
    Coppola A, Simone CD, Palmieri NM, Coppola D, Lanza F, Ruosi C, Amoriello A, Di Minno G.
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):199-201. PubMed ID: 17287639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.